# NEUWAY Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/neuway-pharma

- Industry: Biotechnology
- Headquarters: Bonn, Germany
- Total disclosed funding: $8.1M
- Latest round: Series B (Aug 9, 2023)
- Investors on record: 6

## About

Based in Bonn, Germany, and founded in 2014, Neuway Pharma GmbH is a spin-off from Life Science Inkubator (LSI) GmbH that engages in pre-clinical and clinical development of therapeutics for treatment of orphan brain diseases. In August 2023, Neuway Pharma raised Series B funding from ELBE Beteiligungsgesellschaft mbH, with participation from Wellington Partners, as well as PANDA GmbH, Kfw, and LSI-Pre-Seed-Fonds GmbH.

Neuway Pharma develops mRNA-based therapies for rare central nervous system (CNS) diseases using its proprietary EnPC® (Engineered Protein Capsules) delivery platform. The company’s lead candidate targets Metachromatic Leukodystrophy (MLD), a rare lysosomal storage disorder, by delivering mRNA encoding for the missing enzyme Arylsulfatase. The firm’s EnPC® capsules enable targeted delivery to brain cells, overcoming the blood-brain barrier.

## Funding rounds

- Series B, Aug 9, 2023 — Wellington Partners, KfW Banking Group, PANDA GmbH, LSI-Pre-Seed-Fonds GmbH, ELBE Beteiligungsgesellschaft mbH
- Series A, Apr 27, 2023, $1M — Wellington Partners, KfW Banking Group, PANDA GmbH, LSI-Pre-Seed-Fonds GmbH, ELBE Beteiligungsgesellschaft mbH
- Series A, Oct 29, 2015, $3.5M — Wellington Partners, KfW Banking Group, Life Science Inkubator
- Series A, May 27, 2014, $3.7M — Wellington Partners, KfW Banking Group, PANDA GmbH, LSI-Pre-Seed-Fonds GmbH

## Investors

- Wellington Partners (https://capitalatlas.ai/funds/wellington-partners) — Series A, Series B
- KfW Banking Group — Series A, Series B
- PANDA GmbH — Series A, Series B
- LSI-Pre-Seed-Fonds GmbH — Series A, Series B
- Life Science Inkubator — Series A
- ELBE Beteiligungsgesellschaft mbH — Series A, Series B